Cytosorbents Corp. CTSO
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Cytosorbents Corp. (CTSO) Core Market Data and Business Metrics
Latest Closing Price
$1Price-Earnings Ratio
-2.78Total Outstanding Shares
54.83 Million SharesDividend
No dividendSIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
NASDAQHeadquarters
305 College Road East, Princeton, NJ, 08540
Historical Stock Splits
If you bought 145 shares of CTSO before June 28, 2006, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| December 5, 2014 | 1-for-25 (Reverse Split) |
| June 28, 2006 | 1-for-5.8 (Reverse Split) |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 103,321 Shares | 17.83 | 3/14/2025 | 1,842,019 Shares |
| 126,245 Shares | 14.65 | 2/28/2025 | 1,850,036 Shares |
| 178,212 Shares | 10.95 | 2/14/2025 | 1,950,582 Shares |
| 80,276 Shares | 24.1 | 1/31/2025 | 1,934,385 Shares |
| 996,776 Shares | 1.84 | 1/15/2025 | 1,833,139 Shares |
| 177,629 Shares | 8.15 | 12/31/2024 | 1,447,610 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-18.49 Million |
| Net Cash Flow From Investing Activities | $-681,159 |
| Net Cash Flow From Financing Activities, Continuing | $21.37 Million |
| Net Cash Flow From Financing Activities | $21.37 Million |
| Net Cash Flow | $2.20 Million |
| Net Cash Flow From Investing Activities, Continuing | $-681,159 |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Other Operating Expenses | $2.06 Million |
| Net Income/Loss | $-18.67 Million |
| Costs And Expenses | $59.98 Million |
| Operating Expenses | $45.82 Million |
| Income/Loss From Continuing Operations After Tax | $-18.67 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-19.36 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-19.36 Million |
| Other Comprehensive Income/Loss | $-13.52 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Equity | $13.00 Million |
| Other Non-current Liabilities | $12.57 Million |
| Current Assets | $16.60 Million |
| Liabilities And Equity | $47.80 Million |
| Equity Attributable To Parent | $13.00 Million |
| Noncurrent Assets | $31.21 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||